Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

LncRNA BLAT1 is Upregulated in Basal-like Breast Cancer through Epigenetic Modifications.

Yoo Jane Han | Sonja M Boatman | Jing Zhang | Xinxin C Du | Albert C Yeh | Yonglan Zheng | Jeffrey Mueller | Olufunmilayo I Olopade
Scientific reports | 2018

Long-noncoding RNAs (lncRNAs) have been shown to participate in oncogenesis across a variety of cancers and may represent novel therapeutic targets. However, little is known about the role of lncRNAs in basal-like breast cancer (BLBC), the aggressive form of breast cancer with no molecularly defined therapeutic target. To examine whether altered lncRNA expression contributes to the aggressive phenotype characteristic of BLBC, we performed a comparative analysis of BLBC versus non-BLBC using microarray profiling and RNA sequencing of primary breast cancer. We identified RP11-19E11.1 as a significantly up-regulated lncRNA in BLBC tumors and named it Basal-Like breast cancer Associated Transcript 1 (BLAT1). Analysis of pan-cancer datasets showed the highest expression of BLAT1 in BLBC tumors compared to all other cancers. Depletion of BLAT1 in breast cancer cells led to significantly increased apoptosis, partly because of accumulation of DNA damage. Mechanistically, BLAT1 expression is regulated at the epigenetic level via DNA methylation at CpG islands in the promoter. Concordantly, patients harboring tumors with BLAT1 hypomethylation showed decreased overall survival. Our results suggest that increased expression of BLAT1 via CpG site hypomethylation may contribute to the aggressive phenotype of BLBC, raising a possibility of new biomarkers for prognosis of aggressive BLBC tumors.

Pubmed ID: 30349062

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


GraphPad Prism (tool)

RRID:SCR_002798

Statistical analysis software that combines scientific graphing, comprehensive curve fitting (nonlinear regression), understandable statistics, and data organization. Designed for biological research applications in pharmacology, physiology, and other biological fields for data analysis, hypothesis testing, and modeling.

View all literature mentions

Cell Signaling Technology (tool)

RRID:SCR_004431

Privately held company that develops and produces antibodies, ELISA kits, ChIP kits, proteomic kits, and other related reagents used to study cell signaling pathways that impact human health.

View all literature mentions

HTSeq (tool)

RRID:SCR_005514

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on February 28,2023. Software Python package that provides infrastructure to process data from high-throughput sequencing assays. While the main purpose of HTSeq is to allow you to write your own analysis scripts, customized to your needs, there are also a couple of stand-alone scripts for common tasks that can be used without any Python knowledge.

View all literature mentions

Promega (tool)

RRID:SCR_006724

An Antibody supplier

View all literature mentions

UCSC Cancer Genomics Browser (tool)

RRID:SCR_011796

A suite of web-based tools to visualize, integrate and analyze cancer genomics and its associated clinical data. It is possible to display your own clinical data within one of their datasets.

View all literature mentions

Abcam (tool)

RRID:SCR_012931

A commercial antibody supplier which supplies primary and secondary antibodies, biochemicals, proteins, peptides, lysates, immunoassays and other kits.

View all literature mentions

BD Biosciences (tool)

RRID:SCR_013311

An Antibody supplier

View all literature mentions

Hs 578T (tool)

RRID:CVCL_0332

Cell line Hs 578T is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

T-47D (tool)

RRID:CVCL_0553

Cell line T-47D is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

MDA-MB-468 (tool)

RRID:CVCL_0419

Cell line MDA-MB-468 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

MDA-MB-157 (tool)

RRID:CVCL_0618

Cell line MDA-MB-157 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

HCC1937 (tool)

RRID:CVCL_0290

Cell line HCC1937 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

MCF-7 (tool)

RRID:CVCL_0031

Cell line MCF-7 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

HCC70 (tool)

RRID:CVCL_1270

Cell line HCC70 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

MDA-MB-231 (tool)

RRID:CVCL_0062

Cell line MDA-MB-231 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

HCC1806 (tool)

RRID:CVCL_1258

Cell line HCC1806 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions